


PHARMACEUTICAL 2020

CANNAPHARMARX INC. Rank 312 of 362





PHARMACEUTICAL 2020

CANNAPHARMARX INC. Rank 312 of 362

The relative strengths and weaknesses of CANNAPHARMARX INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CANNAPHARMARX INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 202% points. The greatest weakness of CANNAPHARMARX INC. is the variable Other Expenses, reducing the Economic Capital Ratio by 412% points.

The company's Economic Capital Ratio, given in the ranking table, is -570%, being 267% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,931
Cost of Goods Sold	0
Intangible Assets	6,370
Liabilities, Current	3,952
Liabilities, Non-Current	0
Other Assets	7,716
Other Compr. Net Income	138
Other Expenses	15,500
Other Liabilities	7,211
Other Net Income	-4,473
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	478

Output Variable	Value in 1000 USD
Assets	16,017
Liabilities	11,163
Expenses	15,978
Stockholders Equity	4,854
Net Income	-20,451
Comprehensive Net Income	-20,382
Economic Capital Ratio	-570%